PTC Therapeutics(CH:P91)
CH:P91
PTC Therapeutics financials statements
PTC Therapeutics (P91) Ratios
1 Followers
PTC Therapeutics Ratios
CH:P91's free cash flow for Q3 2026 was $-27.97M. For the 2026 fiscal year, CH:P91's free cash flow was decreased by $-2.66M and operating cash flow was $-25.31M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.35 | 2.35 | 2.02 | 1.71 | 1.87 |
| Quick Ratio | 2.27 | 2.31 | 1.97 | 1.65 | 1.84 |
| Cash Ratio | 1.02 | 1.34 | 0.98 | 0.69 | 0.37 |
| Solvency Ratio | 0.23 | -0.10 | -0.14 | -0.21 | -0.24 |
| Operating Cash Flow Ratio | 0.73 | -0.19 | -0.26 | -0.88 | -0.49 |
| Short-Term Operating Cash Flow Coverage | 1.25 | -0.42 | -0.82 | -4.94 | -1.20 |
| Net Current Asset Value | $ -830.13M | $ -1.44B | $ -1.50B | $ -1.36B | $ -982.25M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.93 | 1.45 | 1.18 | 0.86 | 0.65 |
| Debt-to-Equity Ratio | -13.19 | -2.25 | -2.72 | -4.21 | 882.73 |
| Debt-to-Capital Ratio | 1.08 | 1.80 | 1.58 | 1.31 | 1.00 |
| Long-Term Debt-to-Capital Ratio | 1.11 | 2.09 | 1.75 | 1.38 | 1.00 |
| Financial Leverage Ratio | -14.12 | -1.55 | -2.32 | -4.91 | 1347.74 |
| Debt Service Coverage Ratio | 1.21 | -0.28 | -0.81 | -2.08 | -1.27 |
| Interest Coverage Ratio | 5.63 | -1.81 | -3.40 | -4.92 | -4.35 |
| Debt to Market Cap | 0.43 | 0.68 | 1.02 | 0.49 | 0.42 |
| Interest Debt Per Share | 35.95 | 34.33 | 31.51 | 21.64 | 19.23 |
| Net Debt to EBITDA | 1.94 | -14.04 | -4.95 | -3.21 | -2.93 |
| Profitability Margins | |||||
| Gross Profit Margin | 95.85% | 92.89% | 93.02% | 93.61% | 94.00% |
| EBIT Margin | 49.05% | -24.31% | -60.45% | -71.07% | -80.27% |
| EBITDA Margin | 51.29% | -14.93% | -35.22% | -52.63% | -68.36% |
| Operating Profit Margin | 49.49% | -37.50% | -46.86% | -64.03% | -69.52% |
| Pretax Profit Margin | 40.25% | -45.01% | -74.23% | -84.07% | -96.24% |
| Net Profit Margin | 39.44% | -45.03% | -66.81% | -80.00% | -97.27% |
| Continuous Operations Profit Margin | 39.44% | -45.03% | -66.81% | -80.00% | -97.27% |
| Net Income Per EBT | 97.99% | 100.05% | 90.02% | 95.15% | 101.07% |
| EBT Per EBIT | 81.33% | 120.01% | 158.39% | 131.31% | 138.43% |
| Return on Assets (ROA) | 23.55% | -21.31% | -33.05% | -32.78% | -27.03% |
| Return on Equity (ROE) | -332.49% | 33.08% | 76.55% | 161.06% | -36432.61% |
| Return on Capital Employed (ROCE) | 44.37% | -26.92% | -34.00% | -34.43% | -26.21% |
| Return on Invested Capital (ROIC) | 33.37% | -21.69% | -26.32% | -30.76% | -22.72% |
| Return on Tangible Assets | 28.12% | -24.16% | -43.70% | -60.94% | -46.33% |
| Earnings Yield | 11.30% | -10.47% | -30.38% | -20.42% | -18.67% |
| Efficiency Ratios | |||||
| Receivables Turnover | 9.53 | 5.09 | 5.83 | 4.49 | 4.88 |
| Payables Turnover | 1.58 | 3.32 | 10.83 | 1.64 | 1.40 |
| Inventory Turnover | 0.90 | 2.47 | 2.14 | 2.05 | 2.04 |
| Fixed Asset Turnover | 12.78 | 6.86 | 5.24 | 3.99 | 4.14 |
| Asset Turnover | 0.60 | 0.47 | 0.49 | 0.41 | 0.28 |
| Working Capital Turnover Ratio | 1.66 | 1.15 | 2.08 | 1.91 | 0.77 |
| Cash Conversion Cycle | 212.07 | 109.38 | 199.33 | 36.67 | -6.18 |
| Days of Sales Outstanding | 38.30 | 71.73 | 62.59 | 81.28 | 74.85 |
| Days of Inventory Outstanding | 405.14 | 147.49 | 170.43 | 178.16 | 179.02 |
| Days of Payables Outstanding | 231.38 | 109.85 | 33.69 | 222.77 | 260.05 |
| Operating Cycle | 443.45 | 219.23 | 233.02 | 259.44 | 253.88 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 8.94 | -1.40 | -2.12 | -4.97 | -3.57 |
| Free Cash Flow Per Share | 5.17 | -2.37 | -3.73 | -7.10 | -4.78 |
| Dividend Paid and CapEx Coverage Ratio | 2.37 | -1.45 | -1.31 | -2.34 | -2.95 |
| Capital Expenditure Coverage Ratio | 2.37 | -1.45 | -1.31 | -2.34 | -2.95 |
| Operating Cash Flow Coverage Ratio | 0.26 | -0.04 | -0.07 | -0.24 | -0.20 |
| Operating Cash Flow to Sales Ratio | 0.41 | -0.13 | -0.17 | -0.51 | -0.47 |
| Free Cash Flow Yield | 6.81% | -5.24% | -13.53% | -18.60% | -12.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 8.85 | -9.54 | -3.29 | -4.90 | -5.36 |
| Price-to-Sales (P/S) Ratio | 3.49 | 4.30 | 2.20 | 3.92 | 5.21 |
| Price-to-Book (P/B) Ratio | -29.43 | -3.16 | -2.52 | -7.89 | 1951.79 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 14.69 | -19.07 | -7.39 | -5.38 | -8.34 |
| Price-to-Operating Cash Flow Ratio | 8.49 | -32.21 | -13.02 | -7.68 | -11.17 |
| Price-to-Earnings Growth (PEG) Ratio | -0.03 | 0.22 | -0.44 | -1.01 | -0.45 |
| Enterprise Value Multiple | 8.75 | -42.84 | -11.19 | -10.66 | -10.56 |
| Enterprise Value | 7.76B | 5.16B | 3.70B | 3.92B | 3.89B |
| EV to EBITDA | 8.75 | -42.84 | -11.19 | -10.66 | -10.56 |
| EV to Sales | 4.49 | 6.40 | 3.94 | 5.61 | 7.22 |
| EV to Free Cash Flow | 18.88 | -28.36 | -13.25 | -7.70 | -11.54 |
| EV to Operating Cash Flow | 10.92 | -47.92 | -23.34 | -10.99 | -15.46 |
| Tangible Book Value Per Share | -8.50 | -16.91 | -17.11 | -15.83 | -11.43 |
| Shareholders’ Equity Per Share | -2.58 | -14.29 | -10.94 | -4.84 | 0.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.02 | -0.00 | 0.10 | 0.05 | -0.01 |
| Revenue Per Share | 21.76 | 10.50 | 12.53 | 9.74 | 7.64 |
| Net Income Per Share | 8.58 | -4.73 | -8.37 | -7.79 | -7.43 |
| Tax Burden | 0.98 | 1.00 | 0.90 | 0.95 | 1.01 |
| Interest Burden | 0.82 | 1.85 | 1.23 | 1.18 | 1.20 |
| Research & Development to Revenue | 0.26 | 0.66 | 0.71 | 0.93 | 1.00 |
| SG&A to Revenue | 0.20 | 0.37 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.04 | 0.09 | 0.14 | 0.16 | 0.19 |
| Income Quality | 1.04 | 0.30 | 0.25 | 0.64 | 0.48 |
Currency in USD
